241 related articles for article (PubMed ID: 35159934)
1. Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling.
Panuzzo C; Jovanovski A; Ali MS; Cilloni D; Pergolizzi B
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35159934
[TBL] [Abstract][Full Text] [Related]
2. MRD in AML: The Role of New Techniques.
Voso MT; Ottone T; Lavorgna S; Venditti A; Maurillo L; Lo-Coco F; Buccisano F
Front Oncol; 2019; 9():655. PubMed ID: 31396481
[TBL] [Abstract][Full Text] [Related]
3. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
[TBL] [Abstract][Full Text] [Related]
4. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
Della Starza I; Chiaretti S; De Propris MS; Elia L; Cavalli M; De Novi LA; Soscia R; Messina M; Vitale A; Guarini A; Foà R
Front Oncol; 2019; 9():726. PubMed ID: 31448230
[No Abstract] [Full Text] [Related]
5. Measurement of Residual Disease in Acute Myeloid Leukemia.
Vedula RS; Lindsley RC
Curr Hematol Malig Rep; 2017 Dec; 12(6):574-581. PubMed ID: 29064024
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in
Patkar N; Kodgule R; Kakirde C; Raval G; Bhanshe P; Joshi S; Chaudhary S; Badrinath Y; Ghoghale S; Kadechkar S; Khizer SH; Kannan S; Shetty D; Gokarn A; Punatkar S; Jain H; Bagal B; Menon H; Sengar M; Khattry N; Tembhare P; Subramanian P; Gujral S
Oncotarget; 2018 Nov; 9(93):36613-36624. PubMed ID: 30564301
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
8. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation.
Takamatsu H
J Clin Med; 2017 Sep; 6(10):. PubMed ID: 28946710
[TBL] [Abstract][Full Text] [Related]
10. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
11. Droplet Digital PCR for
Bochicchio MT; Petiti J; Berchialla P; Izzo B; Giugliano E; Ottaviani E; Errichiello S; Rege-Cambrin G; Venturi C; Luciano L; Daraio F; Calistri D; Rosti G; Saglio G; Martinelli G; Pane F; Cilloni D; Gottardi EM; Fava C
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771634
[No Abstract] [Full Text] [Related]
12. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
13. Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia.
Flach J; Shumilov E; Wiedemann G; Porret N; Shakhanova I; Bürki S; Legros M; Joncourt R; Pabst T; Bacher U
Hematol Oncol; 2020 Oct; 38(4):425-431. PubMed ID: 32306411
[TBL] [Abstract][Full Text] [Related]
14. Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring.
Crowgey EL; Mahajan N; Wong WH; Gopalakrishnapillai A; Barwe SP; Kolb EA; Druley TE
BMC Med Genomics; 2020 Mar; 13(1):32. PubMed ID: 32131829
[TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of MRD in AML].
Ishikawa Y
Rinsho Ketsueki; 2020; 61(9):1150-1159. PubMed ID: 33162510
[TBL] [Abstract][Full Text] [Related]
16. Double Drop-Off Droplet Digital PCR: A Novel, Versatile Tool for Mutation Screening and Residual Disease Monitoring in Acute Myeloid Leukemia Using Cellular or Cell-Free DNA.
Rausch C; Rothenberg-Thurley M; Buerger SA; Tschuri S; Dufour A; Neusser M; Schneider S; Spiekermann K; Metzeler KH; Ziemann F
J Mol Diagn; 2021 Aug; 23(8):975-985. PubMed ID: 34020042
[TBL] [Abstract][Full Text] [Related]
17. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Kotrova M; Trka J; Kneba M; Brüggemann M
Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
[TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
Shapiro RM; Kim DDH
Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease in acute myelogenous leukemia.
Cruz NM; Mencia-Trinchant N; Hassane DC; Guzman ML
Int J Lab Hematol; 2017 May; 39 Suppl 1(Suppl 1):53-60. PubMed ID: 28447422
[TBL] [Abstract][Full Text] [Related]
20. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
